Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program

Core Viewpoint - Aurora Cannabis Inc. has announced the establishment of a new at-the-market offering program allowing the issuance and sale of up to U.S.$100 million of common shares to the public at the company's discretion [1]. Group 1: Offering Details - The net proceeds from the offering will be used for strategic and accretive purposes, including increased cultivation capacity and mergers and acquisitions (M&A) [2]. - Common shares will be sold through "at-the-market distributions" on the NASDAQ or other U.S. marketplaces at the prevailing market price, with no sales occurring in Canada [3]. - The sales will be conducted under a sales agreement with TD Securities (USA) LLC dated February 4, 2026 [4]. Group 2: Regulatory Filings - A prospectus supplement has been filed with securities commissions in Canada (excluding Quebec) and with the U.S. Securities and Exchange Commission (SEC) as part of the company's registration statement under the U.S./Canada Multijurisdictional Disclosure System [5]. Group 3: Company Overview - Aurora Cannabis is a global leader in medical cannabis, focusing on improving lives through scientific expertise and a commitment to patient care, serving both medical and consumer markets across multiple regions [7]. - The company has a portfolio of trusted brands and holds a controlling interest in Bevo Farms Ltd., a leading supplier of propagated agricultural plants [7].